other material
confidence high
sentiment positive
materiality 0.65
Guided Therapeutics passes regulatory review in China; receives $133K payment from SMI
GUIDED THERAPEUTICS INC
- Clinical trial at Fudan University approved; trials at 4 centers start Q3 2021.
- SMI paid $133,000 first installment; total $510,635 due during study.
- Expected payments up to $3M by end 2022 if NMPA approval granted.
- Minimum orders of $72M over 4 years post Chinese FDA approval.
- LuViva disposable royalty set at $1.90 per unit, adjusted for inflation.